Research at H. Lee Moffitt Cancer Center & Research Institute identified immune dysregulation as a key factor hindering CAR T-cell expansion and effectiveness in diffuse large B-cell lymphoma patients. The study suggests that addressing underlying immune characteristics may improve treatment outcomes.
A phase 1b/2 trial shows that combining eprenetapopt with azacitidine improves overall response rate to 71% in TP53 mutant MDS and AML patients. The median overall survival is 10.8 months, with improved outcomes for those who responded to treatment.
Researchers at Moffitt Cancer Center discovered that cancer cells can fuse and recombine their genetic material, leading to increased diversity and adaptability. This mechanism, similar to parasexual recombination in pathogenic microbes, enables cancer cells to rapidly evolve and acquire resistance to treatments.
Cancer cells can thrive in hostile environments through metabolic adaptation known as the Warburg Effect. Moffitt researchers found that activation of transcription factor KLF4 allows cells to select for this phenotype, enabling them to survive and thrive in poor conditions.
Researchers at Moffitt Cancer Center have identified a novel biochemical pathway that protects cells from ferroptosis, a type of cell death caused by oxidation imbalance. The discovery involves the activation of the protein GCLC, which leads to the production of gamma-glutamyl-peptides that shield cells against ferroptosis.
A new study published in Cancer suggests that inflammation from ADT is linked to higher levels of fatigue in prostate cancer patients. The researchers found an increase in the inflammation marker IL-6 in this group, which may contribute to symptoms.
Researchers at H. Lee Moffitt Cancer Center have identified SATB1 as a potential new drug target for treating cutaneous T cell lymphoma. Decreased expression of this protein contributes to the development of CTCL, and drugs that restore its expression may be effective against the disease.
Researchers identified genomic heterogeneity and immune content scores that predict lethal outcomes in grade 4/5 prostate cancer patients. The study found that approximately 25% of these patients were more likely to benefit from targeted treatment strategies.
The Patient Researcher Forum allows patients and researchers to learn from each other, fostering interdisciplinary collaboration. The program has a positive impact on perspectives of both parties, with patients gaining insight into the importance of cancer research and researchers becoming more patient-centered in their work.
African American men are more susceptible to prostate cancer due to immune-oncologic differences, which can be exploited for personalized treatment options. The study found elevated immune pathways and higher expression of T lymphocytes in African American prostate tumors, suggesting better responses to radiotherapy and immunotherapy.
A new deep learning model using PET/CT imaging can classify EGFR mutation status in non-small cell lung cancer, predicting the most effective treatment option. The model shows promise as a clinical decision support tool for personalized treatment choices.
Researchers at Moffitt Cancer Center discovered specific molecules, TAp63, long noncoding RNA (lncRNA), and proteins WDR26 and NOLC1 that regulate AKT signaling pathway to promote tumor development and progression.
Researchers identified EphA2 as a key driver of metastasis and BRAF-MEK inhibitor resistance in melanoma. The study found that the noncanonical pathway of EphA2 induces an amoeboid phenotype that enhances metastatic potential.
A novel acidic niche in lymph nodes regulates T cell activation, suppressing effector functions that could damage the system. The findings highlight the importance of localized acidosis in shaping T cell biology.
Researchers found that high levels of pre-treatment interleukin 6 indicate a high risk for neurotoxicity and cytokine release syndrome from CAR T therapy. The study also suggests that targeting the tumor microenvironment prior to therapy may help reduce inflammation and toxicities.
Moffitt researchers found that umbralisib, a PI3K/CK1ε inhibitor, showed fewer immune-mediated side effects compared to traditional PI3K inhibitors. The study suggests that dual inhibition may improve safety profiles for CLL patients.
Moffitt researchers discovered deltaNp63 protein plays a key role in facilitating cancer spread by oscillating its expression. The protein is overexpressed in many primary tumors and metastases, and its silence is required for cancer cells to undergo EMT.
A new radiomics model can identify early stage lung cancer patients at high risk for poor survival outcomes and require aggressive follow-up or adjuvant therapy. The model uses two radiomic features to stratify patients into three risk groups, which may have more aggressive cancer despite early detection.
A Moffitt Cancer Center study found that CAR T-cell therapy, Yescarta, is effective in patients with relapsed/refractory large B cell lymphoma who would not have qualified for clinical trials. The study showed an overall response rate of 82% and durable response rate of 47%, suggesting that these patients can benefit from the therapy.
A new mathematical model predicts prostate cancer tumor growth and invasiveness based on stromal ecology, revealing that highly reactive stroma drives aggressive tumors. The model was validated in animal models and patients, suggesting improved prognosis with ecological metrics.
Researchers at Moffitt Cancer Center have identified the PERK protein as a critical molecular pathway controlling immunosuppression in tumor cells. By targeting PERK, cancer patients may experience reactivation of their immune system and enhanced effectiveness of immunotherapy treatments.
Researchers developed a mathematical model that forecasts patient responses to intermittent androgen deprivation therapy based on changing levels of the biomarker PSA. The model predicted 89% accuracy in developing patient resistance, enabling personalized treatment options.
Researchers at Moffitt Cancer Center identified potential therapeutic targets for cutaneous squamous cell carcinoma by studying the activity of protein TAp63 and microRNAs. The study found that miR-30c-2* and miR-497, which are normally expressed in normal skin, are underexpressed in cuSCC tumors and inhibit growth when reintroduced.
Researchers at Moffitt Cancer Center found that targeting histone deacetylase HDAC11 blocks cancer stem cell self-renewal and overcomes drug resistance in non-small cell lung cancer. The study suggests that HDAC11 inhibitors may be a potential therapeutic strategy for NSCLC.
Researchers at Moffitt Cancer Center present a case study of an adaptive treatment approach based on evolutionary principles in prostate cancer, suggesting it as a promising alternative to traditional treatments. The approach involves forcing tumors into repeatable treatment cycles, which may limit the development of uncontrollable dru...
The study found that cerebrospinal fluid from LMM patients contains proteins critical to melanoma cell survival and growth, including TGF-β1. The researchers hope their data will provide insights into potential therapeutic targets for delayed disease progression.
Researchers at Moffitt Cancer Center have developed a new platform for creating genetically engineered mice to study melanoma, which is significantly faster than the traditional approach. This new method uses chimera mouse models and chimera-derived melanoma cell lines to provide a faster way to study skin cancer.
A community-based program enables patients to donate tumor tissue and blood samples for research, allowing researchers to study genetic and molecular makeup of tumors after treatment failure. Analysis reveals similar DNA mutations and varying protein biomarker expression among samples from the same patient.
Moffitt researchers discovered that the STING protein signaling pathway induces an inflammatory response and enables immune cells to recognize human melanoma cells. Activation of STING results in production of interferon-beta and CXCL10, stimulating inflammation and immune response.
Researchers found that differences at the single-cell level can predict responses to BRAF inhibitor therapy, and leveraging these differences may improve patient outcomes. Maintaining a population of cells within the drug-sensitive State 1 was critical to maintaining drug sensitivity.
Researchers at Moffitt Cancer Center have identified a new mechanism controlling DNA repair, where βarrestin-1 targets 53BP1 for protein degradation. This finding provides a novel strategy for developing therapeutic agents with radiation protection properties.
Researchers at H. Lee Moffitt Cancer Center describe a promising new treatment combination for patients with non-small cell lung cancer, showing preliminary efficacy and improved tolerance compared to standard treatments.
Researchers at Moffitt Cancer Center have developed a model called GARD that uses genomic data to predict the risk of local tumor recurrence and optimize radiation doses for breast cancer patients. The study found that a personalized approach to radiation therapy can reduce overdosing certain patients and improve treatment outcomes.
Researchers analyzed genomic data from 317 MCC patients and found two distinct populations with different genetic profiles and treatment responses. Immunotherapies showed high effectiveness in both groups, with better response rates when given early treatment.
Researchers at Moffitt Cancer Center have discovered a new treatment approach that may help nearly a third of lung cancer patients with KRAS mutations. The combination therapy targets the MEK kinase and enhances anti-tumor immunity through cytokines TNFα and IFNγ.
Moffitt researchers identified three subtypes of squamous cell lung cancer (SCC) with distinct genetic, chromosomal, and protein alterations. The inflamed subtype is characterized by immune cell infiltration and higher PD-1 levels, while the redox subtype has altered oxidation-reduction signaling pathways. These subtypes did not correl...
A new study has found that elderly cancer patients who are HIV-positive have poorer outcomes compared to those without the virus. The research found higher mortality rates from breast and prostate cancers among HIV-infected patients.
Researchers propose a 'first-strike' and 'second-strike' strategy to tackle metastatic cancer. The approach aims to eliminate the entire cancer population by sequencing drugs, rather than relying on maximum tolerated dose therapy. This could lead to better outcomes for patients with widespread disease.
Researchers at Moffitt Cancer Center have identified a new drug combination that is effective against metastatic uveal melanoma cells. The combination of an MEK inhibitor and a histone deacetylase (HDAC) inhibitor, such as panobinostat, has been shown to prevent resistance to the MEK inhibitor and enhance its anti-tumor properties.
BCL-2 protein deregulation and transcriptional reprogramming contribute to Venetoclax resistance; researchers suggest targeting CDK7 as effective strategy to prevent resistance. Studies provide insights into drug resistance mechanism in B-cell lymphomas, paving way for potential co-treatment strategies.
Researchers at H. Lee Moffitt Cancer Center discovered a signaling pathway between cytokines and BRAF that promotes tumor growth. Blocking ITCH activity or BRAF ubiquitination may be an effective treatment approach to slow tumor growth in melanoma.
Moffitt researchers discovered that melanoma cells become resistant to BRAF inhibitors through a conserved stress response mechanism involving AP-1 activation and histone deacetylase 8. This finding suggests that HDAC inhibitors may be able to overcome resistance mechanisms, leading to potential new treatments.
A new online tool allows researchers to determine the genetic ancestral origin of over 1300 cancer cell lines, revealing a lack of representation from diverse populations. The study found that European and East Asian origins were overrepresented, while African American and Hispanic/Latino origins were underrepresented.
Researchers found that Chop expression is higher in T cells from ovarian cancer patients, and high nuclear levels of Chop are associated with poor clinical responses. Blocking Chop or ER stress may help improve T cell-based immunotherapy treatments.
Researchers discovered that second-generation CARs stimulate CD3 signaling more effectively than third-generation receptors and activate downstream signaling messengers. This may contribute to superior antitumor efficacy. The study aims to improve CAR designs and lead to better understanding of immunotherapy.
A new study published in the Journal of Clinical Oncology highlights gaps in attitudes, knowledge, and practices towards LGBTQ patients among oncologists. The research identified a need for education and training on LGBTQ-related issues to improve care for this patient population.
The study found nearly 40% of large B cell lymphoma patients remained in remission beyond 2 years after receiving Yescarta treatment. Patients with refractory disease showed durable responses, giving hope for a cure.
A new study highlights the effectiveness of CAR T-cell therapy in treating diffuse large B cell lymphoma patients. The real-world outcomes show that 81% of patients responded to the therapy with 58% having no detectable cancer after four months.
A new study found that daily low-dose aspirin use reduces the risk of ovarian cancer by 23 percent. In contrast, heavy use of non-aspirin NSAIDs increases the risk. The research analyzed data from over 200,000 women and confirms earlier findings about aspirin's role in reducing certain types of cancers.
A new study finds that baseline PSA levels in black men between 40 and 60 can strongly predict future development of prostate cancer and its most aggressive forms. Elevated PSA levels are associated with increased risk, even among those within the normal range.